We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content
SpringerLink
Log in

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

HER-2/neu overexpression has been associated with poor prognosis in human breast cancer. Many of these cancers are also ER-positive. A logical therapeutic approach for patients who are ER-positive and overexpress HER-2/neu may be to block both the ER and the HER-2/neu pathways. In our study, we used both the MTT tetrazolium dye assay and 3H-thymidine incorporation to measure the effects of the anti-estrogen Tamoxifen or the 4D5 anti-HER-2/neu antibody alone or in combination on the growth of BT474 human breast cancer cells which express ER and overexpress HER-2/neu. We found an enhanced inhibitory effect on cell proliferation with the combination of Tamoxifen and the antibody compared to that seen by either agent alone. This simultaneous interruption of both the ER and the HER-2/neu pathways may be relevant in the clinical treatment of patients who are both ER-positive and overexpress HER-2/neu.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maguire HC, Greene MI: The neu (c-erbB-2) oncogene. Semin Oncol 16: 148–155, 1989

    Google Scholar 

  2. King CR, Kraus MH, Aaronson SA: Amplication of a novel v-erbB-2 related gene in a human mammary carcinoma. Science 229: 974–976, 1985

    Google Scholar 

  3. Lupu R, Lippman ME: The role of erbB-2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 27: 83–93, 1993

    Google Scholar 

  4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989

    Google Scholar 

  5. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120–1128, 1989

    Google Scholar 

  6. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332–4337, 1990

    Google Scholar 

  7. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH: Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49: 2087–2090, 1989

    Google Scholar 

  8. Ro JS, el-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G: c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49: 6941–6944, 1989

    Google Scholar 

  9. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8: 103–112, 1990

    Google Scholar 

  10. McCann A, Dervan PA, Johnston PA, Gullick WJ, Charney DN: c-erbB-2 oncoprotein expression in primary human tumors. Cancer 65: 88–92, 1990

    Google Scholar 

  11. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51: 944–948, 1991

    Google Scholar 

  12. Zhou DJ, Ahuja H, Cline MJ: Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105–108, 1989

    Google Scholar 

  13. Paterson MC, Dietrich KD, Danyluk J, Paterson H, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon DJ, Fourney RM: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51: 556–567, 1991

    Google Scholar 

  14. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Eng J Med 319: 1239–1245, 1988

    Google Scholar 

  15. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50: 6701–6707, 1990

    Google Scholar 

  16. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235: 177–182, 1987

    Google Scholar 

  17. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296–3303, 1991

    Google Scholar 

  18. Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947–3951, 1990

    Google Scholar 

  19. Colomer R, Saceda M, Martin BM, Lippman ME, Lupu R: Cross-regulation of erbB2 oncoprotein and estrogen receptor by estrogen and the erbB2 ligands (gp30/p75). Proc AACR 33: Abs 494, 1992

    Google Scholar 

  20. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Breast Cancer Res Treat 24: 85–95, 1992

    Google Scholar 

  21. Nicholson S, Wright S, Sainsbury RC, Halcrow P, Kelly P, Angus B, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Molec Biol 37: 811–814, 1990

    Google Scholar 

  22. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129–1135, 1995

    Google Scholar 

  23. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H: ErbB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6: 137–143, 1991

    Google Scholar 

  24. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL: High-dose oral Tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with Vinblastine. J Natl Cancer Inst 84: 1811–1816, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, USA

    Lois M. Witters & Allan Lipton

  2. Center for Biostatistics and Epidemiology, Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, USA

    Rakesh Kumar & Vernon M. Chinchilli

Authors
  1. Lois M. Witters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rakesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vernon M. Chinchilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Allan Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Witters, L.M., Kumar, R., Chinchilli, V.M. et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42, 1–5 (1997). https://doi.org/10.1023/A:1005798224288

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005798224288

Search

Navigation